Pages that link to "Q38700339"

The following pages link to A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma (Q38700339):

Displaying 11 items.

• Development of expression-based biomarkers of Dasatinib response in hematologic malignancies (Q47248214) ‎ (← links)
• The proteasome and proteasome inhibitors in multiple myeloma (Q47339695) ‎ (← links)
• Identification of gene signatures from RNA-seq data using Pareto-optimal cluster algorithm (Q60937700) ‎ (← links)
• Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity (Q64262106) ‎ (← links)
• Characterization of carfilzomib-resistant non-small cell lung cancer cell lines (Q88687685) ‎ (← links)
• [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients] (Q88739454) ‎ (← links)
• Potential Clinical Application of Genomics in Multiple Myeloma (Q89066166) ‎ (← links)
• A Network Analysis of Multiple Myeloma Related Gene Signatures (Q90384099) ‎ (← links)
• The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies (Q91229404) ‎ (← links)
• Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma (Q93162999) ‎ (← links)
• In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma (Q98158633) ‎ (← links)